ColonFlag™ is a decision support software tool that identifies individuals who are at high risk of having colorectal cancer (CRC) using conventional blood test results, age and gender. ColonFlag™ can identify signals indicating increased risk for CRC at its early stages, often months before clinical signs are present.
ColonFlag™ is used by healthcare organizations as a clinical decision support system, alerting doctors to patients who are at high risk of having CRC. With ColonFlag™, healthcare organizations can reach out to individuals who are at increased risk for and prioritize them for further evaluation. The ability to pinpoint high-risk patients can help optimize the use of colonoscopy resources and potentially improve patient care.
ColonFlag™ utilizes Big Data to analyze thousands of complex parameters, trends and interrelationships within mass CBC data. Our technology can bring to light intelligent data-driven insights relating to cancer risks, which may otherwise be invisible under current standard scrutiny. ColonFlag™ is part of the revolution that applies machine learning technology to healthcare, designed to help save lives, drive medical efficiency and reduce costs through improved tools supporting early detection and treatment.
The ColonFlag model was developed and validated with with datasets from nearly 1 million patients in Israel and U.K., as well as ongoing clinical data trials including over 20 million patients in 14 sites at leading institutions worldwide.
Implemented at Maccabi Healthcare, an HMO covering 2 million lives, ColonFlag™ analyzes existing medical data and identifies a subgroup in the general population that has a high probability of harboring colorectal cancer or precancerous lesions. Requiring no patient involvement, the system automatically alerts Maccabi GPs who then decide whether further CRC evaluation is warranted. Please see here for the clinical results of the first year of operations and Becker’s GI & Endoscopy for some related press coverage.
ColonFlag bears CE and is not yet cleared by FDA for commercial use in the USA